Sequenom Files for FDA Clearance of Impact Dx System, Thrombophilia Test | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market on Wednesday that it has filed for marketing clearance from the US Food and Drug Administration of its Impact Dx System and Impact Dx Factor V Leiden and Factor II Genotyping Test.

The system and test are intended for use in clinical laboratories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.